Date: 2011-05-20
Type of information: Licensing agreement
Compound: ulipristal acetate
Company: HRA Pharma (France) ASKA Pharmaceutical (Japan)
Therapeutic area: Gynecology - Women's health
Type agreement: licensing
development
commercialisation
Action mechanism:
Disease: uterine fibroids
Details: ASKA Pharmaceutical Co., LTD and HRA Pharma have announced the conclusion of exclusive licensing agreements for ASKA Pharmaceutical to develop and market ulipristal acetate in Japan. The agreement covers a product which has an important role in the treatment of multiple women’s reproductive health issues, and specifically the treatment of uterine fibroids. Uterine fibroids are the most common type of non-cancerous hormone-dependent tumor of the female reproductive system. The condition affects between 20-50% of women, and is most common in women between the ages of 35 and 50. In European studies, ulipristal acetate has been shown to be an effective and safe treatment for uterine fibroids (myoma), a condition that affects millions of women worldwide. The product is currently in late-stage development in Europe and will be marketed under the trade name EsmyaTM*. Aska expects to initiate Japanese clinical studies without delay.
Financial terms: Financial details of the agreement were not disclosed.
Latest news:
